Dyno Therapeutics

Director, Supply Chain Planning

Waltham, Massachusetts, United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, HealthcareIndustries

Requirements

The Director of Supply Chain Planning requires a Bachelor's degree and at least 10 years of experience in supply chain planning, preferably within the pharmaceutical or biotechnology industry. Strong analytical and problem-solving skills are essential, along with experience in long-range planning and scenario-based analysis. Familiarity with GMP and regulatory requirements is also necessary.

Responsibilities

The Director will collaborate with cross-functional teams to develop and maintain a reliable demand and supply plan, ensuring uninterrupted clinical supply and commercial launch readiness. They will monitor external manufacturing site capacities, identify opportunities for supply chain optimization, lead scenario planning to mitigate risks, and manage relationships with third-party suppliers. Additionally, the Director will author SOPs, perform data analysis, and ensure compliance with regulatory standards.

Skills

Supply Chain Planning
Demand Planning
Inventory Management
Production Planning
Risk Assessment
Scenario Planning
Cross-functional Collaboration
CMC
Logistics
Quality
Clinical Operations
Commercial

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Key Metrics

Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.
Manufacturing bottlenecks could hinder scaling of Dyno's operations.
Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.
Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.
Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.
Collaboration with NVIDIA enhances biological sequence design for gene therapies.
Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI